M
Mylan Pharmaceuticals
Mylan agreed to a $73.5 million settlement over claims it conspired to suppress generic EpiPens and extend its monopoly.
ClosedUnited States-wideClaim status: Closed on May 29, 2025Payout: TBDNo longer claimable
About this settlement
Claims relate to alleged illegal suppression of generic EpiPens to extend Mylan's monopoly on the product.
This settlement resolves allegations that Mylan conspired with other companies to block generic EpiPens, maintaining a monopoly and inflating prices. Eligible purchasers of EpiPen or generic EpiPen products may file claims for compensation.
Who qualifies
- Entities that purchased EpiPen or generic EpiPen products directly from Mylan or Teva.
- Purchases made between March 13, 2014 and February 6, 2025.
TBD
Claim status: Closed on May 29, 2025